“Philina’s depth of both precision oncology and radiopharmaceutical industry experience will be valuable to us as we continue to progress our Targeted Alpha Therapies (TAT) platform and grow our pipeline of clinical candidates,” said Fusion Chief Executive OfficerJohn Valliant, Ph.D. “Additionally, her leadership and understanding relating to the commercial launch of an alpha therapy product will provide Fusion with important organizational, strategic and operational guidance during this growth period.”Dr. Lee joined Blueprint Medicines in 2014 and has served in positions of increasing responsibility, including leading new product strategy, establishing the commercial organization, building infrastructure to enable patient access, and leading multiple new product launches. In her current role she is responsible for providing strategic and operational leadership across the portfolio, leading the portfolio management team as well as the program leadership and program management functions.Prior to joining Blueprint Medicines, Dr. Lee served as head of U.S. marketing at Algeta ASA, where she was the second hire in the U.S. In this role, she contributed to building the fully-integrated organization that successfully launched Xofigo® (radium-223 dichloride), a first-in-class alpha-emitting radiopharmaceutical. Algeta was acquired by Bayer AG in 2014.Dr. Lee holds a Ph.D. from theMassachusetts Institute of Technologyand a B.S. from theUniversity of Alberta.”I see significant potential to use Fusion’s Targeted Alpha Therapies (TAT) platform to build a strong portfolio of precision medicines,” said Dr. Lee. “I’m excited to join the board, as I share the Fusion team’s passion for improving the lives of cancer patients. I look forward to contributing to Fusion’s strategic planning and growth.”The number of seats on the Fusion Board of Directors was increased to eight from seven immediately prior to Dr. Lee’s election.About FusionFusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial.
View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-philina-lee-phd-to-board-of-directors-301226902.html
SOURCE Fusion Pharmaceuticals Inc.View original content to download multimedia:http://www.newswire.ca/en/releases/archive/February2021/11/c8345.html